FDA Warns of Vision Loss Linked to Weight-Loss Drugs
📊 NVO — Piyasa Yorumu
▼ down · 55%FDA's vision loss warning on weight-loss drugs creates negative news flow for sector regulation and safety perception. NVO price at 40.65, just below SMA20 and SMA50, RSI at 48.9 neutral and slightly below MACD signal line; technical picture already weak. News may increase selling pressure in the short term, but impact may be limited as it is unclear whether the warning directly targets NVO products or the general drug class. I expect a mild downward trend in the 1-3 day window, but a sharp decline would require additional confirmation.
📊 LLY — Piyasa Yorumu
▼ down · 55%The FDA's vision loss warning regarding weight-loss drugs could heighten regulatory risk for the GLP-1 class of medications, potentially negatively affecting sector sentiment. Given LLY's strong position in this drug class, the news may create short-term selling pressure. However, with an RSI of 52.9 in neutral territory and the price trading just below the SMA20 and above the SMA50, it does not signal a sharp decline. The MACD is slightly below the signal line, indicating weak momentum. The impact may be limited and volatile; a cautious approach is warranted until the scope of the warning becomes clear.